20Ways Fall Retail 2024

Welcome to interactive presentation, created with Publuu. Enjoy the reading!

IMPROVING PATIENT

C A R E & P H A R M A C Y

P R O F I T A B I L I T Y

C O M M U N I T Y , S P E C I A L T Y , & L T C E D I T I O N

FALL 2024

20 Unique

Products &

Services

Wholesalers &

Distributors

Industry Expert Q&A, Market Leaders

Buyer’s Guide, and More pg. 48

DSCSA Update

What You Need to Know

About the Small Dispenser

Exemption and Other Waivers

or Exemptions pg. 68

SureCost Case Study

How HAC Pharmacies Leverage

Data-Driven Purchasing

Decisions to Save Thousands of

Dollars Every Month pg. 30

Miriam Cho, PharmD

President & Chief Pharmacy Officer

~ MACRx

Long-Term Care Pharmacies

The Role of Pharmacy

Management Software in

Selling a Pharmacy?

Highest Price,

Lowest Risk

Rely on Proven Guidance

from a Dedicated Professional

Nationwide Representation pharmacycbs.com

 No conflict of interest, we do NOT pay for endorsements

 Experienced: Dan has personally sold over 200 pharmacies

 Licensed and insured broker, pharmacist, and former multi-pharmacy owner

 A fiduciary who is focused on your best outcome

 Utilizing nationwide competition from both chain and independent buyers

My only goal is to get you the best deal possible.

Competition and multiple ofers are key. Don't settle for one ofer!

Let me work towards your best possible outcome.

Daniel J. Lannon

RPh, Broker/Owner

Call: 888-808-4RPH (4774)

Call/Text: 651-769-4932

Email: dan@pharmacycbs.com

Call Today for a

FREE Consultation

Faster Credit

No Hidden Charges

Simplified Reimbursement

Credit due through the OneCheck

Select program is consolidated

into a single check.

Choose to receive your check

within 10, 30, or 90 days after

your return.

The fee is an all-inclusive

percentage of your returnable

product value.

Contact

Us

If you’re in need of a new returns provider,

Return Solutions is one of the oldest and

most trusted in the industry. With over 30

years of experience and a focus on

independent pharmacies and regional

chains, we put you first so you can focus

on your business and your patients.

The Independent’s

Choice for

Rx Returns

1.800.579.4804

www.drugreturns.com

support@drugreturns.com

Optimize your Rx returns

process and payment.

Return Solutions offers the

fastest credit in the industry.

Sign up today to receive

a special promotion on

your first return!

On-Site service is completely turnkey

Mail-In service is easy and economical

Fastest payment as quickly as 10 days

No additional charges

Contents

page 17

Stat Temp®

From Health

Care Logistics®

Transforms

Temperature

Monitoring

Ensure temperature accuracy

throughout the healthcare

setting with this fully

customizable web-based system

that installs without equipment

and without a subscription.

McKesson’s BlistMED

Revolutionizes

Multi-Dose Blister

Packaging in Retail

Pharmacy

Improve medication management

and employee satisfaction

with BlistMED, an advanced

multi-dose blister packaging

robot that enhances efficiency,

accuracy, and patient safety,

all in a small footprint.

®

page 19

GX Solutions Cold Storage

Safe for Use in Clean Room Environments

HELMER’S EXCLUSIVE OPTICOOL™

TECHNOLOGY FEATURED ON GX SOLUTIONS

MEDICAL-GRADE REFRIGERATORS AND FREEZERS

SUPPORTS TEMPERATURE UNIFORMITY

GX Solutions are the first cold-storage solutions to offer optimized

control in three key temperature management areas: uniformity, stability,

and recovery.

SUPPORTS ENERGY EFFICIENCY AND SUSTAINABILITY

ENERGY STAR® certified and up to 50-65% more energy efficient than

conventional medical-grade cold storage with natural HC refrigerants

that decrease heat output, carbon footprint, and global warming

potential.

SUPPORTS CLEANROOM APPLICATIONS

GX Solutions have been tested and are safe for ISO 5 clean room

applications.

SUPPORTS RELIABILITY

Designed and built to ensure long-lasting reliability, limiting downtime

and interruption to workflow.

GX Solutions Pharmacy Refrigerators

Include NSF/ANSI 456 Certifcation and

ISO Class 5 Clean Room Compatibility

Learn More

© 2024 Helmer Inc. All rights reserved

Helmer GX

Solutions Safe for

Use in Clean Room

Environments ISO

Class 5 and Above

GX Solutions pharmacy

refrigerators include NSF/

ANSI 456 Certification and

ISO Class 5 clean room

compatibility.

page 21

FALL 2024 I RETAIL/COMMUNITY • SPECIALTY • LTC

Pharmacy

Pharmacy

Discover the stories, research,

and reports from real pharmacies.

Case Studies

Case Studies

Visit the library at RXinsider.com

Pharmacy Case

Studies

Discover the stories,

research, and reports from

real pharmacies.

page 22-23

You owe it to yourself to see what PharmaLink can provide. You could realize up

to thousands of dollars in annual return reimbursements value – and more money

to help run your business and realize better profitability.

Call us today for an easy, no obligation comparison at (800) 257-3527.

Hidden fees and murky

payment agreements are

designed to keep you in the

dark about what your real rate

is for the processing of your

returns. Quick pay rates are

often costing you 20% - 40%

of your return value!

HIGHER

RATES

Are you ever shown the exact

value of the manufacturer

credits received? PharmaLink

always provides you with

the ACTUAL value received

from the Manufacturer

– not an estimate.

TRANSPARENCY

ZERO

Overall value of your

returned products can be

deflated to cover shortages in

manufacturer disbursements

instead of using ACTUAL

manufacturer’s credit value

used by PharmaLink.

DEFLATED

ESTIMATES

Quick pay programs benefit returns companies, not YOU!

Your quick pay returns program

literally could be costing you thousands

© PharmaLink Inc. 0724

REVERSE DISTRIBUTION SERVICES

If you’re on a quick pay returns program, it’s likely coming at a big cost...

LEARN MORE

Simple to store.

Longer shelf life.

Treatment in the convenience

of a room temperature,

intramuscular injection.

INDICATIONS & USAGE1

LEUPROLIDE ACETATE INJECTION DEPOT (leuprolide acetate

for depot suspension) 22.5 mg for 3-month administration

(leuprolide acetate) is indicated for palliative treatment of

advanced prostate cancer.

IMPORTANT SAFETY INFORMATION1

Contraindications: Hypersensitivity: LEUPROLIDE ACETATE

INJECTION DEPOT is contraindicated in individuals with known

hypersensitivity to GnRH agonists or any of the excipients

in LEUPROLIDE ACETATE INJECTION DEPOT. Anaphylactic

reactions to GnRH agonists have been reported.

Warnings And Precautions:

x

Tumor Flare: LEUPROLIDE ACETATE INJECTION DEPOT

causes increases in serum levels of testosterone during

the first weeks of treatment. Isolated cases of ureteral

obstruction and spinal cord compression have been

observed, which may contribute to paralysis with or without

fatal complications. Transient worsening of symptoms may

develop. Patients may experience a temporary increase in

bone pain. Patients with metastatic vertebral lesions and/or

with urinary tract obstruction should be closely observed.

x

Hyperglycemia and Diabetes: Hyperglycemia and an

increased risk of developing diabetes have been reported in

men receiving GnRH agonists. Monitor blood glucose and/or

glycosylated hemoglobin (HbA1c) periodically

in patients receiving a GnRH.

x

Cardiovascular Diseases: Increased risk of developing

myocardial infarction, sudden cardiac death and stroke has

been reported, and should be evaluated carefully along with

cardiovascular risk factors. Patients receiving a GnRH agonist

should be monitored for symptoms and signs suggestive of

development of cardiovascular disease and be managed

accordingly.

x

Effect on QT/QTc Interval: Androgen deprivation therapy

may prolong the QT/QTc interval. Providers should consider

whether the benefits of androgen deprivation therapy

outweigh the potential risks in patients with congenital

long QT syndrome, congestive heart failure, frequent

electrolyte abnormalities, and in patients taking drugs

known to prolong the QT interval. Electrolyte abnormalities

should be corrected. Consider periodic monitoring of

electrocardiograms and electrolytes.

REFERENCES:

1. LEUPROLIDE PRESCRIBING INFORMATION, CIPLA, 2018.

2. Data on file. CIP-REF-LEU-001. Warren, NJ: Cipla USA; 2022

Medical Information:

Report Adverse Events/Side Effects | Report Product Complaints | Submit Medical Inquiries:

Contact Us: 1-866-604-3268 DrugSafety@cipla.com

Leuprolide Acetate

Injection Depot

(Leuprolide Acetate for Depot Suspension)

22.5 mg*

*Each syringe contains 22.5 mg

(provided as Leuprolide acetate)

WHOLESALER/DISTRIBUTOR ORDER ENTRY NUMBER

CENCORA

CARDINAL

MCKESSON

MORRIS & DICKSON

10274981

5815139

2655967

190595

To place your order, please contact your wholesaler.

Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059

Customer Service Tel.: 844-CIPLA US (844-247-5287)

Email: Cipla.CS@cipla.com

JUNE 2024 CUSAI-06212024-03

x

Convulsions: Convulsions have been observed and should

be managed accordingly.

x

Laboratory Tests: Monitor serum levels of testosterone

following injection of LEUPROLIDE ACETATE INJECTION

DEPOT 22.5 mg for 3-month administration.

x

Embryo-Fetal Toxicity: LEUPROLIDE ACETATE INJECTION

DEPOT may cause fetal harm when administered to a

pregnant woman. Advise pregnant patients and females

of reproductive potential of the potential risk to the fetus.

Most common adverse events (incidences >10%) are hot

flushes, upper respiratory infection, fatigue, diarrhea, pollakiuria,

arthralgia, and injection site pain.

Use in specific populations:

Lactation: A decision should be made to discontinue

breastfeeding or discontinue the LEUPROLIDE ACETATE

INJECTION DEPOT.

Females and Males of Reproductive Potential:

LEUPROLIDE ACETATE INJECTION DEPOT may impair fertility

in males of reproductive potential.

Pediatric Use: The safety and effectiveness of LEUPROLIDE

ACETATE INJECTION DEPOT in pediatric patients have not

been established.

Geriatric Use: Hot flushes occurred with equal frequency in

those ≤ 65 years of age.

To report suspected adverse reactions, contact Cipla at

1-866-604-3268 or the FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch.

www.ciplaleuprolide.com

DETAILS

NDC 1

69097-0909-50

STRENGTH1

22.5 mg

ROUTE OF ADMINISTRATION1

Intramuscular

SELLING UNIT

1 kit consisting of a LEUPROLIDE ACETATE INJECTION MIXJECT single-dose delivery system

STORAGE1

Store at controlled room temperature at 20º-25ºC (68º-77ºF)

SHELF LIFE2

36 months from date of manufacture

Please see www.ciplaleuprolide.com

or scan the QR code for full Prescribing

Information and Important Safety

Information.

HCPCS Code: J1954

• Sterile and Paper Free (USP 797 Compliant).

• Maintains a 100% sterile barrier* with 3X greater adhesion.

*Tested in Nelson Labs, Salt Lake City, UT

• Helps prevent contamination of drugs and

provides added protection to pharmacists.

• Will not fall off, even in cold storage conditions

(down to -20 degrees centigrade).

• Patented dual-layer indicates true tamper-

evidence, with “OPENED” marking.

VIEW TRAINING VIDEOS HERE

Made in the USA

Syringe Seals

IV Bag Port Seals

Belly Button

Bag Seal

Vial Seals

28mm

20mm

13mm

The Most Innovative Tamper-Evident

Seals Throughout the Pharmacy Today

steri-tamp.com

Visit Our Website to Request Samples

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80

Made with Publuu - flipbook maker